Molnupiravir, a drug being developed by Merck and Ridgeback Biotherapeutics, has shown positive results in clinical trials in combatting COVID-19 (Economist, Fox News, Merck). “Compassionate use" and "emergency use" authorizations would count (FDA, FDA).

Confused? Check our FAQ or ask us for help. To learn more about Good Judgment and Superforecasting, click here.

To learn more about how you can become a Superforecaster, see here. For other posts from our Insights blog, click here.

NOTE 3 August 2021: FDA approval for molnupiravir for use in combination with other therapeutics to treat COVID-19 would count.

The question closed "No" with a closing date of 1 October 2021.

See our FAQ to learn about how we resolve questions and how scores are calculated.